Starting Atypical Antipsychotics Increases Falls, Fractures
the Psychiatry Advisor take:
Older adults who start a new atypical antipsychotic medication have an increased risk for serious falls and fractures, according to a study published in JAMA Internal Medicine.
For patients aged ≥65 years, starting a new atypical antipsychotic increased their risk of falling by 53% and their risk of non-vertebral osteoporotic fracture by 50%.
The retrospective study included medical records from 200,000 Ontario residents. Patients who started taking one of three atypical antipsychotics – quetiapine (Seroquel), risperidone (Risperdal), or olanzapine (Zyprexa) – from 2003 to 2011 were matched with controls who did not take any of these medications. The researchers looked at fractures and falls that occurred up to 90 days after receiving the new prescription.
Patients who started on atypical antipsychotics had increased risks of hip fracture, non-vertebral osteoporotic fracture, and falls compared with controls. These risks were unrelated to the type of medication, the dosage, or whether the patient lived in a long-term care facility.
Out of those receiving atypical antipsychotics, 7.0% experienced fractures compared with 5.5% of controls. Additionally, 4.4% of those taking the medications experienced falls while only 2.9% of controls did.
The results add to evidence of safety concerns of using atypical antipsychotics in older adults; previous studies have already linked them to hypotension, sedation, and gait abnormalities.
For patients aged ≥65 years, starting a new atypical antipsychotic increased their risk of falling by 53%
Receiving a new prescription for an atypical antipsychotic medicine was associated with more serious falls and more fractures in a new retrospective cohort study.
Adults ages 65 and older who received a new prescription had a 53% increased risk of falling and a 50% increased risk of nonvertebral osteoporotic fracture, found the study. It was published as a research letter in JAMA Internal Medicine on Jan. 13, 2015, and was led by Lisa-Ann Fraser, MD, from the University of Western Ontario in Canada.
"These findings call into question the widespread off-label use of atypical antipsychotic medications and support increasing evidence of safety concerns regarding their use in older adults," Fraser and colleagues wrote.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Etiology of Schizophrenia: Strong Association With Certain Rare Copy Number Variants
- Long-Term Lithium Use: More Evidence Needed to Associate With Cancer Risk
- Evzio Authorized Generic Soon to Be Available
- AMA Survey Collects Advice for Physicians Approaching Retirement
- Revised Children's Anxiety and Depression Scales Reliable Measurement Tool for Adults
- Cannabis Use, Cannabis Use Disorder Linked to Psychotic, Depressive Symptoms
- Abstinence From Regular Cannabis Use Improves Memory Among Adolescents, Young Adults
- Group Cognitive Behavioral Therapy Is Effective Treatment for Adolescent Anxiety
- Association Between Opioid and Benzodiazepine Misuse and Suicidal Ideation
- The Intersection of Eating and Alcohol Disorders: Detecting and Managing "Drunkorexia"
- Cognition, Depression, and Limited Functioning Linked in Middle Age
- Coping With Challenges When Working the Holidays
- Lithium Preferred Method of Maintenance Monotherapy in Older Adults With Bipolar Disorder
- Hypobetalipoproteinemia Associated With Aggression and Schizophrenia
- AMA Code of Medical Ethics Guides Physicians in Fighting Harmful Online Health Information